Molecular Partners AG (MOLN) stock

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30

$3.01−0.08 (-2.59%)

Close on Nov 12, 2026Market cap $121.53MP/E –Yield –

Molecular Partners price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Molecular Partners's price to sales ratio was 31.4× on Feb 27, 2026, against 26.0× a year earlier. Over the last 5 years it ranged from 0.6× to 79.4×, with a median of 21.6×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Feb 27, 2026	31.4×	+7.7
2025	Dec 31, 2025	23.7×	+3.6
2024	Dec 31, 2024	20.0×	+19.4
2023	Dec 29, 2023	0.6×	−18.6
2022	Dec 30, 2022	19.2×	−35.5
2021	Dec 31, 2021	54.7×	–

Where these numbers come from

Parsed from the XBRL in Molecular Partners's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MOLN.

Compare: MOLN vs CRIS · MOLN vs TCRX · MOLN vs IPHA · MOLN vs RLAY · MOLN vs ELOX

Revenue growth-100.0% · median -38.4%

Company	Revenue	Growth
RLAY	$10.35M	+23.9%
TCRX	$5.19M	-38.4%
CRIS	$4.31M	-62.2%
MOLN	CHF 0	-100.0%
IPHA	–	–
ELOX	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 34
Held by institutions: 8.9%
Auditor: KPMG AG
SEC CIK: 1745114

Advertisement
300 × 250

See a number that looks wrong?

Molecular Partners price to sales ratio

Price to Sales Ratio at the end of each year

More Molecular Partners figures